BYRON FUSELIER: Open Payments
NPI 1225746597 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,385 in 50 payments from 11 companies in 2025. Trend: 2023 $400 · 2024 $1,058 · 2025 $1,385
Food & beverage: $1,385
| Company | Payments | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 7 | $209 |
| BridgeBio Pharma, Inc. | 7 | $192 |
| AstraZeneca Pharmaceuticals LP | 9 | $179 |
| Merck Sharp & Dohme LLC | 8 | $162 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $148 |
| CVRx, Inc. | 3 | $132 |
| Veloxis Pharmaceuticals, Inc. | 2 | $127 |
| SCPHARMACEUTICALS INC. | 3 | $98 |
| Kestra Medical Technology Services, Inc. | 2 | $88 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 1 | $25 |
Products named: AMVUTTRA, Attruby, JARDIANCE, WAINUA, Barostim Neo System, ENVARSUS, VERQUVO, FUROSCIX.
Industry payments across NY — which companies pay providers there.
